BIO5 Institute aims to harness the collaborative power of five core research areas—agriculture, engineering, medicine, science, and pharmacy—to find bold solutions to complex problems.
Housed in the Thomas W. Keating Bioresearch Building, the University of Arizona’s BIO5 Institute was launched in 2001 and aims to harness the collaborative power of five core research areas: agriculture, engineering, medicine, science, and pharmacy.
By facilitating collaborations between expert researchers in each of these disciplines from across the UA campus, the BIO5 Institute is positioned to address some of the grand challenges facing society today. Researchers at BIO5 are exploring bold solutions to complex problems, such as disease, food insecurity, and climate change and applying interdisciplinary expertise along the way.
CyVerse, a National Science Foundation-funded data management platform, represents one of the largest projects operating under the BIO5 Institute.
CyVerse is one of eight projects funded by the National Science Foundation’s (NSF) Directorate for Biological Sciences. It was launched in 2008 with a $50 million grant from the NSF to provide computational infrastructure for plant sciences. The project's early success led to a renewal grant in 2013, also worth $50 million, but with the expanded directive to serve all life sciences’ data management needs.
Much like streamlining data management in the Information Age, all BIO5 research projects are aimed at real-world impact. BIO5 researchers develop and commercialize new technologies, diagnostics, and treatments, and have formed 20 spinoff companies in the last eight years. BIO5 is also invested in education and public outreach, supporting K-12 teachers, developing innovative high-school internship programs, training students, providing industry internships, and facilitating a learning environment where students work side-by-side with top scientists in BIO5 labs.
At BIO5, researchers ask big questions, inspire bold solutions, and improve health and life for better tomorrows.